Biodexa Pharmaceuticals (BDRX) Common Equity (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Common Equity across 13 years of filings, most recently posting $15.2 million for Q4 2025.

• In Q4 2025, Common Equity rose 42.03% year-over-year to $15.2 million; the TTM figure through Dec 2025 stood at $15.2 million (up 42.03% YoY), while the FY2025 annual figure was $15.0 million, up 41.36% from the prior year.
• Common Equity came in at $15.2 million for Q4 2025 at Biodexa Pharmaceuticals, down from $15.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $15.3 million in Q2 2025 to a low of $3.7 million in Q4 2022.
• Average Common Equity over 5 years is $9.7 million, with a median of $10.1 million recorded in 2022.
• Year-over-year, Common Equity sank 73.68% in 2022 and soared 83.97% in 2024.
• Over 5 years, Common Equity stood at $14.1 million in 2021, then slumped by 73.68% to $3.7 million in 2022, then jumped by 56.55% to $5.8 million in 2023, then jumped by 83.97% to $10.7 million in 2024, then jumped by 42.03% to $15.2 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $15.2 million in Q4 2025, $15.3 million in Q2 2025, and $10.7 million in Q4 2024.